25 Mar 2013, BioSpectrum Bureau , BioSpectrum
Singapore: Zenalux Biomedical launched the Zenascope PC1, a biological tissue spectrometer that reliably, quickly and non-destructively measures biological tissue characteristics (biomarkers) that reflect underlying function and composition. The device can be used to detect the presence of cancer as well as other disease states and has also shown significant promise in monitoring therapy.
The Zenascope PC1 is an ultraviolet-visible spectrometer that achieves quantitative optical spectroscopy in turbid media. The system is a specialized, real-time, diagnostic device that shines white light on opaque target media and then measures and analyzes the reflected signal.
Proprietary algorithms and standardized measurement hardware achieve rapid, quantitative analysis of targeted endpoints including hemoglobin concentration, hemoglobin saturation and scattering (a measure of cell density and necrosis).
The system can also easily be tuned to include additional absorbers of interest. This unique capability is expected to enable improved diagnosis, better treatment and ultimately cost reduction in the health care system. Application areas currently include accelerating feedback in drug discovery; breast tumor margin assessment; response to therapy; breast biopsy; cervical cancer detection; and head and neck cancer detection.
Dr Mark W Dewhirst, Gustavo S Montana Professor of radiation oncology and director of the radiation oncology program at the Duke Comprehensive Cancer Center, said that, "This technique gives us a fundamentally new approach to monitoring tumor physiology non-destructively and in real time. Using this approach we are in a much better position to evaluate treatment response and adjust our treatment strategies accordingly."